It enables the application of existing PSMA-PET/CT response metrics, such as the PSMA-PET/CT Progression (PPP), focuses on the response of single lesions in PSMA-PET and the RECIP that relies on the PSMA-PET–derived total tumor volume and is more appropriate for extensive disease (Figure 5). This evidence concerns the gene FOLH1 and neoplasm.